AstraZeneca (AZN): news on Friday 2 October 2026

The 17 stories

Each headline's own score, strongest first. Links go to the publisher.

• +5.8 ORPATHYS plus TAGRISSO FDA application supports AstraZeneca stock after support test Traders Union
  FDA application for Orpathys plus Tagrisso supports outlook.
• +5.3 Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway businesswire.com
  Clinical trial collaboration involving its Datroway ADC; pipeline expansion.
• +5.0 AstraZeneca and two partners plan to test a cancer-drug pairing in breast cancer stocktitan.net
  Collaboration to test cancer-drug combination in breast cancer; pipeline progress.}
• +4.2 AstraZeneca (LSE:AZN) Oncology Filing Puts Valuation and Growth Back in Focus Kalkine Media
  Oncology filing puts growth and valuation in focus.
• −3.7 AstraZeneca Stocks Drops as $2 Billion Buys an Oncology Option TradingView
  Shares dropped as $2bn buys only an option.
• +3.3 AstraZeneca Young Health Programme and UNICEF extend collaboration to advance adolescent health in Indonesia UNICEF
  Youth health programme collaboration extended; reputational positive.
• −3.3 AstraZeneca invests USD 2 billion in Summit. AstraZeneca stock falls 1.24 percent. AD HOC NEWS
  Shares fall after $2bn Summit investment.
• +3.3 AstraZeneca Young Health Programme, UNICEF Partner to Advance Health Equity in Egypt Sada Elbalad English
  Health programme partnership with UNICEF; reputational positive.
• +3.0 AstraZeneca (AZN) Puts $2 Billion Into Summit Therapeutics (SMMT) for a Cancer Tie-Up Insider Monkey
  $2bn investment in Summit gives oncology option; strategic but costly.
• +2.5 AstraZeneca acquires stake in Summit Therapeutics for $2 billion AKM.RU
  Reports $2bn stake acquisition in Summit.
• −2.0 AstraZeneca stock after-hours at EUR 141.75: minus 1.05 percent versus prior close AD HOC NEWS
  Shares slightly lower after hours.
• +1.7 What Does Summit Therapeutics (SMMT) Gain From This $2 Billion Cancer Partnership? Yahoo Finance UK
  Focus on Summit's gain; AstraZeneca a named partner.
• +1.7 Friday Five: Sanofi and Regeneron (re)partner up in the face of Dupixent's patent cliff, AstraZeneca invests $2B in Summit, Lilly delivers more weight loss wins…and more FirstWord Pharma
  Summit investment mentioned in weekly roundup among other stories.
• −1.7 Should investors care about AstraZeneca’s succession planning? Investors' Chronicle
  Questions raised over succession planning.
• −1.7 AstraZeneca stock pre-market at EUR 142.18: minus 0.75 percent AD HOC NEWS
  Shares slightly lower pre-market.
• +1.3 Why Is AstraZeneca (LSE:AZN) Stock In Focus Today After Its Summit Therapeutics Investment? Kalkine Media
  Stock in focus after Summit investment; neutral-ish coverage.
• +0.8 Hong Kong needs new funding model to attract global drug makers: AstraZeneca South China Morning Post
  Company comments on Hong Kong funding model; mostly neutral.